Danielle Hulsman

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibition.

PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibition.

Journal: Communications biology

Published: March 02, 2025

Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma.

Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma.

Journal: British journal of cancer

Published: October 13, 2023

Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma.

Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma.

Journal: Cancer research communications

Published: June 22, 2023

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.

Journal: Cell reports. Medicine

Published: June 29, 2022

Functional antagonism of chromatin modulators regulates epithelial-mesenchymal transition.

Functional antagonism of chromatin modulators regulates epithelial-mesenchymal transition.

Journal: Science advances

Published: July 14, 2020

Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing.

Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing.

Journal: Cancer discovery

Published: February 24, 2020

USP15 Deubiquitinase Safeguards Hematopoiesis and Genome Integrity in Hematopoietic Stem Cells and Leukemia Cells.

USP15 Deubiquitinase Safeguards Hematopoiesis and Genome Integrity in Hematopoietic Stem Cells and Leukemia Cells.

Journal: Cell reports

Published: January 29, 2020

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

Journal: The Journal of experimental medicine

Published: April 26, 2018

TRIM28 is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming.

TRIM28 is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming.

Journal: Stem cells (Dayton, Ohio)

Published: January 05, 2016

Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.

Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.

Journal: Cancer cell

Published: March 12, 2015

In vivo shRNA screens in solid tumors.

In vivo shRNA screens in solid tumors.

Journal: Nature protocols

Published: November 21, 2014

Tight regulation of ubiquitin-mediated DNA damage response by USP3 preserves the functional integrity of hematopoietic stem cells.

Tight regulation of ubiquitin-mediated DNA damage response by USP3 preserves the functional integrity of hematopoietic stem cells.

Journal: The Journal of experimental medicine

Published: August 13, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026